Approximately 20-30% of non-muscle invasive bladder urothelial carcinomas invade the lamina propria and are staged as T1. They represent a therapeutic challenge because of their highly malignant potential.
Their individual clinical behavior is difficult to predict, and despite recent developments, their molecular profile and position in pathogenic pathways remain enigmatic.